In ₹ Crore except Per Share Latest Annual	AARTIDRUGS FY26	ALIVUS FY24	AARTIPHARM FY26	ADVENZYMES FY26	Peer Average
Valuation — at last close
P/E	21.02×	—	48.14×	◆ 17.52×	32.83× -36%
P/B	2.65×	—	3.96×	◆ 1.81×	2.88× -8%
EV/EBITDA	15.09×	—	24.61×	◆ 10.16×	17.39× -13%
Market Cap	₹4,098 Cr	—	₹8,410 Cr	₹2,956 Cr	₹5,683 Cr -28%
Growth
Revenue CAGR 3Y	-1.89%	—	-2.20%	◆ 11.32%	4.56% -141%
Revenue CAGR 5Y	3.55%	—	—	◆ 8.24%	8.24% -57%
Net Income CAGR 3Y	5.43%	—	-3.35%	◆ 18.68%	7.67% -29%
Revenue YoY (latest Q)	19.01%	—	◆ 45.92%	2.08%	24.00% -21%
Net Income YoY (latest Q)	-7.12%	—	◆ 155.96%	-4.58%	75.69% -109%
Profitability
EBITDA Margin	12.05%	29.53%	20.29%	◆ 30.72%	26.85% -55%
Net Income Margin	7.60%	20.62%	9.60%	◆ 23.28%	17.83% -57%
Return on Common Equity	13.36%	◆ 21.07%	8.40%	11.05%	13.51% -1%
Return on Capital Employed	13.34%	◆ 26.94%	11.05%	11.61%	16.53% -19%
Return on Assets	7.23%	◆ 16.96%	5.47%	10.03%	10.82% -33%
Credit & Quality
Total Debt/Equity	0.37×	—	0.32×	◆ 0.01×	0.17× +124%
Interest Coverage	7.19×	◆ 401.55×	5.65×	71.91×	159.70× -95%
Scale — latest FY
Revenue / Total Income	₹2,565 Cr	₹2,283 Cr	₹1,819 Cr	₹746 Cr	₹1,616 Cr +59%
Net Income	₹195 Cr	₹471 Cr	₹175 Cr	₹174 Cr	₹273 Cr -29%
Total Assets	₹2,815 Cr	₹2,850 Cr	₹3,482 Cr	₹1,839 Cr	₹2,724 Cr +3%
EPS	₹21.36	—	₹19.27	₹15.08	₹17.18 +24%
Book Value per Share	₹169.7	—	₹234.35	₹145.81	₹190.08 -11%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.